Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.

Loren, A W; Luger, S M; Stadtmauer, E A; Tsai, D E; Schuster, S; Nasta, S D; Goldstein, S C; Perl, A; Orloff, G; Oliver, J C; Green, J; Emerson, S G; Porter, D L

Loren, A W; Luger, S M; Stadtmauer, E A; Tsai, D E; Schuster, S; Nasta, S D; Goldstein, S C; Perl, A; Orloff, G; Oliver, J C; Green, J; Emerson, S G; Porter, D L.

Affiliation

Loren AW; Bone Marrow and Stem Cell Transplant Programs, University of Pennsylvania Cancer Center, Philadelphia, PA, USA. awokoff@mail.med.upen.edu

Bone Marrow Transplant ; 35(9): 921-6, 2005 May.

Article in En | MEDLINE | ID: mdl-15765118

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Vidarabine / Antineoplastic Combined Chemotherapy Protocols / Hematopoietic Stem Cell Transplantation / Transplantation Conditioning / Graft vs Host Disease / Lymphoproliferative Disorders / Mycophenolic Acid Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2005 Document type: Article Affiliation country: Estados Unidos

Search on Google

Add to My VHL

XML

PubMed Links